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Objective: Mutations in the aryl hydrocarbon receptor-interacting protein (AIP) were recently shown to
confer a pituitary adenoma predisposition in patients with familial isolated pituitary adenomas (FIPA).
We report a large Samoan FIPA kindred from Australia/New Zealand with an R271W mutation that
was associated with aggressive pituitary tumors.
Design and methods: Case series with germline screening of AIP and haplotype analyses among R271W
families.
Results: This previously unreported kindred consisted of three affected individuals that either presented
with or had first symptoms of a pituitary macroadenoma in late childhood or adolescence. The index
case, a 15-year-old male with incipient gigantism and his maternal aunt, had somatotropinomas, and
the maternal uncle of the index case had a prolactinoma. All tumors were large (15, 40, and 60 mm
maximum diameter) and two required transcranial surgery and radiotherapy. All three affected subjects
and ten other unaffected relatives were found to be positive for a germline R271W AIP mutation.
Comparison of the single nucleotide polymorphism patterns among this family and two previously
reported European FIPA families with the same R271W mutation demonstrated no common ancestry.
Conclusions: This kindred exemplifies the aggressive features of pituitary adenomas associated with AIP
mutations, while genetic analyses among three R271W FIPA families indicate that R271W represents a
mutational hotspot that should be studied further in functional studies.
European Journal of Endocrinology 161 799–804Introduction
Pituitary adenomas occur frequently in the general
population, with clinically diagnosed tumors having a
prevalence of one case per 1064 individuals (1, 2). In
general, pituitary adenomas occur most frequently in
adults, with pituitary adenomas in the pediatric or
adolescent setting being quite uncommon (3, 4).
However, early onset of pituitary adenomas in children
and adolescents can be associated with aggressive
disease and more dramatic phenotypic features, such
as gigantism (3).
Although many molecular genetic abnormalities
have been reported in pituitary tumors, most are
somatic in nature and are not associated with a defined
clinical phenotype (4, 5). Very few germline genetic
mutations are associated with pituitary adenomas in a
sporadic or familial context. Well-characterized syn-
dromes include multiple endocrine neoplasia type 1ndocrinology(MEN1) or more rarely Carney complex (CNC) (6, 7).
Pituitary adenomas can occur in kindreds in the
absence of MEN1/CNC, a clinical condition known as
familial isolated pituitary adenomas (FIPA) (7). Recently,
Vierimaa et al. discovered that mutations in the aryl
hydrocarbon receptor (AhR)-interacting protein gene
(AIP) on chromosome 11q13 were associated with a
pituitary adenoma predisposition (PAP) among kindreds
in Finland and Italy with acromegaly and prolactino-
mas (8). AIP mutations were subsequently shown to
account for about 15% of FIPA kindreds (5, 9);
nonsecreting adenomas can also be associated with
AIP mutations (5). International genetic screening
studies have identified other AIP mutations among
familial and sporadic pituitary adenoma populations
(9–15). These series, albeit involving limited numbers of
affected patients, suggest that tumors in patients with
AIP mutations are larger and occur at a younger age
than sporadic cases (16).DOI: 10.1530/EJE-09-0406
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in multiple unrelated kindreds and appear to represent
hotspots. One missense AIP mutation, R271W, has
been reported in two European FIPA kindreds with
acromegaly. We report a large Polynesian kindred with
the R271WAIP mutation with three affected members,
each of whom demonstrated distinct phenotypic
features of highly aggressive pituitary adenomas.Case reports
The genealogy of the family is shown in Fig. 1
and includes three patients with pituitary adenomas
(II-1, II-5, and III-6).Case 1 (patient III-6)
Patient III-6 presented with headaches and visual
disturbances at the age of 15.5 years. His weight was
104 kg and height was 193 cm, both in excess of the
97th centile (C2.5 S.D). His height was excessive in
comparison with his calculated mid-parental height of
185 cm (90th centile). The characteristic overgrowth
of the extremities and typical facial appearance of
acromegaly were absent. He was euthyroid and
appropriately advanced in puberty with 15 ml testi-
cular volume and normal secondary sexual charac-
teristics. No visual field defect was apparent on clinical
examination. Initial investigation revealed an insulin-
like growth factor 1 (IGF1) of 658 mg/l, normal for the
patient’s age and sex. No other hormonal abnormal-
ities were present. On magnetic resonance imaging
(MRI), the patient had a pituitary macroadenoma
of 15 mm in maximum diameter without invasionwww.eje-online.orgof surrounding structures and with posterior displace-
ment of the pituitary stalk (Fig. 2). Over the following
14 months, the patient remained under close review
and no change in the pituitary adenoma charac-
teristics was noted. Despite an adult bone age, absent
distinctive acromegalic features, and normal age/sex-
matched IGF1 levels, the patient gained a further
2.8 cm in height over this period. GH hypersecretion
was confirmed on oral glucose tolerance test (OGTT),
with an elevated basal GH (7.3 mg/l), which failed to
suppress (nadir GH 4.2 mg/l). The patient is currently
awaiting transsphenoidal excision of the tumor.
Following discussions with the patient’s family, it
came to light that his maternal uncle (patient II-1) and
aunt (patient II-5) both had a past history of pituitary
adenomas that had been treated in New Zealand.Case 2 (patient II-1)
This patient is the 32-year-old maternal uncle of
patient III-6. He presented in 1988 at 12 years of age
with a history of severe headaches and reduced visual
acuity in his right eye. Pallor of the right optic disc and
a bitemporal hemianopia were present on exami-
nation. Hormonal analysis revealed an elevated
prolactin (PRL) level of 247 000 mU/l (normal up to
450 mU/l), and a CT scan of the brain demonstrated a
giant (40 mm diameter) pituitary adenoma with
suprasellar extension. Owing to his visual impairment
and the size of the tumor, a craniotomy with partial
decompression was performed in December 1988.
Histology showed a pleomorphic chromophobe ade-
noma with a moderately high mitotic rate; immuno-
chemistry was strongly positive for PRL and negative
for GH and ACTH. He was treated with bromocriptine,Figure 1 Genealogical tree of three
generations of a Samoan FIPA kindred with
an R271W AIP mutation.
Figure 2 Sagittal MRI scan of patient III-6 demonstrating a large
noninvasive pituitary macroadenoma.
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February–April 1989. No tumor regrowth occurred
but panhypopituitarism subsequently developed. With
hormonal replacement (including GH therapy), the
patient reached a final height of 169 cm.
Case 3 (patient II-5)
The third patient, the maternal aunt of patient III-6 and
sister of patient II-1, presented (in 1990) at 22 years of
age with a 3-year history of amenorrhea, galactorrhea,
and headaches. At the presentation, she had acrome-
galic features and a diagnosis of acromegaly was made
based on an elevated IGF1 level of 240 mg/l (normal
range on in-house RIA: 17–66 mg/l) and a plasma GH of
11 mg/l, which rose toO30 mg/l following an OGTT. In
addition, she had an elevated PRL level of 981 mU/l
(normal !600 mU/l) and multiple anterior pituitary
hormonal deficiencies including ACTH deficiency,
hypogonadotrophic hypogonadism, and secondary
hypothyroidism. A 60 mm pituitary macroadenoma
extending 50 mm above the pituitary fossa with frontal
lobe distortion was found on CT imaging of the brain.
She underwent craniotomy and partial tumor decom-
pression in 1990, followed by external beam pituitary
irradiation and medical therapy with bromocriptine for
2 years. She developed panhypopituitarism and required
thyroxine, hydrocortisone, and estrogen replacement.
At last follow-up aged 39 years, she had normal GH,
IGF1, and PRL levels, indicating tumor remission.Genetic analyses
Given the family occurrence of pituitary adenomas in
this kindred, genetic screening was undertaken. MEN1
and CNC were outruled by clinical and genetic criteria.Sequencing of the AIP gene was then performed. The
DNA was extracted from peripheral lymphocytes and
analyzed for AIP mutations by direct sequencing, as
previously described by Vierimaa et al. (8). The structure
of the AIP gene was based on Ensembl sequences
ENST00000279146 and ENSG00000110711.
DNA analysis in patient III-6 revealed a previously
described R271W (c.811 COT) AIP mutation. Based on
this finding, a kindred analysis was undertaken.
Following the provision of informed consent, 16 family
members from three successive generations submitted
blood for germline AIP analysis. The R271W mutation
was also detected in affected patients II-1 and II-6. As
expected, the mother of patient III-6, an obligate carrier,
proved to be mutation positive. In addition, eight other
family members were carriers of the R271W mutation.
All carriers were entirely asymptomatic, and on further
study with MRI of the pituitary gland in these subjects,
no pituitary adenomas were identified. The R271WAIP
mutation had been reported by Daly et al. previously in
two European FIPA families (9). As there was no
genealogical evidence of a known common ancestor
among the Samoan and European kindreds, we
undertook single nucleotide polymorphism (SNP)
analysis of the members of identified FIPA R271W
kindreds. SNP analysis excluded a common ancestry
amongst the Polynesian and European kindreds. At
rs2276020, a T/T genotype is not observed in
Caucasian individuals. The members of the Samoan
Australian/New Zealand kindred demonstrated this T/T
genotype, while all members of the European kindreds
had the C/C genotype.Discussion
Pituitary adenomas occur infrequently in the pediatric/
adolescent age group. Familial pituitary adenomas
are also rare, accounting for only 3% of pituitary
adenomas (6). Mutations in the AIP gene are associated
with PAP and account for about 15% of FIPA kindreds
(8, 9). Pituitary adenomas described to date in the
setting of AIP mutations are most often somatotropi-
nomas and prolactinomas; nonsecreting adenomas are
increasingly reported, in addition to one case of
Cushing’s disease (8, 9, 12, 17). From individual
studies and case reports, it appears that patients with
AIP mutations tend to have larger tumors that occur at
a younger age than is usual (16).
The cases described in the current report typify many
aspects of the clinical phenotype in FIPA kindreds with
AIP mutations. Patient III-6 and II-1 presented with
pituitary adenomas at an early age with symptoms first
occurring in early to mid adolescence, and in both
cases, these tumors were macroadenomas. Despite the
identical R271W mutation, the three patients in this
kindred demonstrated phenotypic variability (somato-
tropinomas and a prolactinoma). Although bothwww.eje-online.org
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former patient, the tumor was associated with incipient
gigantism but no other hormonal abnormalities and
typical acromegalic features were absent. In patient
II-5, the tumor was very large and was associated with
clinical acromegaly in addition to hyperprolactinemia
and multiple pituitary hormonal deficits at baseline.
These features serve to underline the variable pheno-
types that can be associated with the same AIP
mutation even within the same family.
The AIP gene is located on chromosome 11q13 (8)
and encodes a protein of 330 amino acids. AIP is a ligand
activated co-chaperone protein that forms a complex
with the AhR in addition to two hsp90 molecules (18).
AIP contains a number of conserved regions including
three tetratricopeptide repeat sequences (TPR), the third
of which is crucial for AhR signal transduction (19).
Mutations within the third TPR domain abolish binding
of AIP to hsp90 and reduce AhR binding by up to 80%
(20). AhR, also known as the dioxin receptor, is widely
accepted to mediate carcinogenic and toxic effects in
animals and humans (21). By means of ligand
activation, the AhR complex modulates gene transcrip-
tion and is involved in cell programing, cell-cycle
regulation through growth factor signaling and pro-
gramed cell death (22). The precise role of AIP in
pituitary tumorigenesis remains obscure at this time,
and it is still uncertain whether tumorigenesis involves
AhR-related pathways or other elements such as
phosphodiesterase activity or newly reported
interactions with RET–survivin (23, 24).
In 2006, Vierimaa et al. first identified a Q14X AIP
mutation in the northern Finnish population, in which
a founder effect for this mutation is clearly present (8).
In the last 3 years, many more AIP mutations have been
reported, some of which lead to protein truncation.
Other missense mutations appear to target amino acid
residues that are vital for correct protein function. The
mutation detected in the current study, R271W, occurs
within the sequence coding for the critically important
third TPR domain. This mutation has been previously
described in two European FIPA kindreds. The pre-
viously reported families were of a father and son, both
with acromegaly (but not gigantism) and the other, a
mother with a somatolactotrope tumor and a son with a
GH-secreting tumor (9). Ancestral linkage between
these European families and this family was excluded
through AIP SNP haplotype analysis, highlighting the
recurrent nature of the mutation and the likely
functional importance of R271W as a mutational hotspot.
AIP mutations are found in 15% of FIPA kindreds (8, 9,
14), but as is the case with MEN1 and PRKAR1A (a gene
for CNC), AIP mutations play a minor role in the
pathogenesis of unselected sporadic pituitary adenoma
cases (10, 11, 13, 25, 26). However, few specific
screening studies have been performed among the
potentially at risk young population. Studies to date
strongly suggest that somatotropinomas in the youngwww.eje-online.org(aged!25–30 years) are quite frequently associated with
germlineAIPmutations (27, 28). Larger studies in young
populations with various pituitary tumor phenotypes are
required to define precisely the more general association
of young age at diagnosis and AIP mutation status.
AIP mutations are thought to confer a moderate to
low penetrance disease. In our three-generational
family, 12 members harbored a pathological AIP
mutation and three of these had pituitary adenomas.
It is common practice to define penetrance among
adults, but seven carriers in our kindred remain under
the age of 18. The penetrance of this pathological
mutation is 37.5% if only those aged O18 years are
considered; currently, 25% of all mutation carriers in
this kindred have pituitary adenomas. This is similar to
reported penetrance figures in other extensively studied
kindreds (8, 14). For this reason, longitudinal data are
needed on previously reported families with known
AIP mutations in order to determine lifetime risks of
developing pituitary adenomas. These data are a
necessary element for accurate counseling of asympto-
matic carriers in these families. In particular, children
identified as carriers may have a lifelong increased risk
of developing pituitary adenomas. The frequency and
type of follow-up required have not been determined;
however, current suggestions are for pituitary imaging
at identification of carrier status and, thereafter, once
yearly hormonal studies involving at least PRL and
IGF1 (16). In the absence of symptoms or signs
suggestive of hormonal or clinical abnormalities, very
frequent pituitary MRI screening is probably not
warranted. As for all familial screening for disease,
the aim in the case of AIP mutation carriers is early
diagnosis to lessen morbidity and facilitate early
definitive treatment. Given the preponderance of
somatotropinomas in pituitary adenoma patients
with AIP mutations, the acknowledged increase in
mortality associated with exposure to elevated GH and
IGF1 levels means that close follow-up of mutation
carriers could facilitate early diagnosis and curative
treatment before major systemic pathological effects of
acromegaly have manifested themselves (29).
In conclusion, this family highlights the importance
of exploring the family history in young patients with
pituitary adenomas and underlies the utility of con-
sidering AIP mutation status and screening in such
young patients and their relatives.Declaration of interest
There is no conflict of interest that could be perceived as prejudicing
the impartiality of the research reported.Funding
This research did not receive any specific grant from any funding
agency in the public, commercial, or not-for-profit sector.
R271WAIP mutation in kindred with FIPA 803EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009) 161Acknowledgements
We gratefully acknowledge Dr Mark Popelier and Dr Arnaud Murat for
their clinical input, Inga-Lill Svedberg for technical assistance and the
Molecular Medicine Sequencing Laboratory at the University of
Helsinki.References
1 Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA &
Beckers A. High prevalence of pituitary adenomas: a cross-
sectional study in the province of Liege, Belgium. Journal of Clinical
Endocrinology and Metabolism 2006 91 4769–4775.
2 Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML &
McCutcheon IE. The prevalence of pituitary adenomas: a
systematic review. Cancer 2004 101 613–619.
3 Besser GM, Burman P & Daly AF. Predictors and rates of treatment-
resistant tumor growth in acromegaly. European Journal of
Endocrinology 2005 153 187–193.
4 Asa SL & Ezzat S. Genetics and proteomics of pituitary tumors.
Endocrine 2005 28 43–47.
5 Beckers A & Daly AF. The clinical, pathological, and genetic
features of familial isolated pituitary adenomas. European Journal of
Endocrinology 2007 157 371–382.
6 Daly AF, Jaffrain-Rea ML & Beckers A. Clinical and genetic features
of familial pituitary adenomas. Hormone and Metabolic Research
2005 37 347–354.
7 Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V,
Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T,
Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F,
Delemer B, Bertherat J, Wemeau JL, De Herder W,
Archambeaud F, Stevenaert A, Calender A, Murat A,
Cavagnini F & Beckers A. Clinical characterization of familial
isolated pituitary adenomas. Journal of Clinical Endocrinology and
Metabolism 2006 91 3316–3323.
8 Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A,
Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R,
Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A &
Aaltonen LA. Pituitary adenoma predisposition caused by
germline mutations in the AIP gene. Science 2006 312
1228–1230.
9 Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA,
Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP,
Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A,
Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabate MI,
Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P,
Wemeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F,
Calender A, Sinilnikova O, Montanana CF, Cavagnini F, Hana V,
Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V,
Brue T, Bours V, Teh BT & Beckers A. Aryl hydrocarbon receptor-
interacting protein gene mutations in familial isolated pituitary
adenomas: analysis in 73 families. Journal of Clinical Endocrinology
and Metabolism 2007 92 1891–1896.
10 Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML,
Trouillas J, Tamagno G, Cazabat L, Bours V, Brue T, Enjalbert A &
Beckers A. Mutations in the aryl hydrocarbon receptor interacting
protein gene are not highly prevalent among subjects with
sporadic pituitary adenomas. Journal of Clinical Endocrinology and
Metabolism 2007 92 1952–1955.
11 Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N,
Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X,
Clauser E, Chanson P, Bertherat J & Raffin-Sanson ML. Germline
inactivating mutations of the aryl hydrocarbon receptor-
interacting protein gene in a large cohort of sporadic
acromegaly: mutations are found in a subset of young patients
with macroadenomas. European Journal of Endocrinology 2007
157 1–8.
12 Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Makinen MJ,
Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T,Robledo M, De Menis E, Weil RJ, Wasik A, Zielinski G, Lucewicz O,
Lubinski J, Launonen V, Vahteristo P & Aaltonen LA. Molecular
diagnosis of pituitary adenoma predisposition caused by aryl
hydrocarbon receptor-interacting protein gene mutations. PNAS
2007 104 4101–4105.
13 Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T &
Yoshimoto K. The aryl hydrocarbon receptor-interacting protein
gene is rarely mutated in sporadic GH-secreting adenomas. Clinical
Endocrinology 2007 66 499–502.
14 Naves LA, Daly AF, Vanbellinghen JF, Casulari LA, Spilioti C,
Magalhaes AV, Azevedo MF, Giacomini LA, Nascimento PP,
Nunes RO, Rosa JW, Jaffrain-Rea ML, Bours V & Beckers A.
Variable pathological and clinical features of a large Brazilian
family harboring a mutation in the aryl hydrocarbon receptor-
interacting protein gene. European Journal of Endocrinology 2007
157 383–391.
15 Toledo RA, Lourenco DM Jr, Liberman B, Cunha-Neto MB,
Cavalcanti MG, Moyses CB, Toledo SP & Dahia PL. Germline
mutation in the aryl hydrocarbon receptor interacting protein
gene in familial somatotropinoma. Journal of Clinical Endocrinology
and Metabolism 2007 92 1934–1937.
16 Cazabat L, Guillaud-Bataille M, Bertherat J & Raffin-Sanson ML.
Mutations of the gene for the aryl hydrocarbon receptor-
interacting protein in pituitary adenomas. Hormone Research
2009 71 132–141.
17 Georgitsi M, Heliovaara E, Paschke R, Kumar AV, Tischkowitz M,
Vierimaa O, Salmela P, Sane T, De Menis E, Cannavo S,
Gundogdu S, Lucassen A, Izatt L, Aylwin S, Bano G, Hodgson S,
Koch CA, Karhu A & Aaltonen LA. Large genomic deletions in
AIP in pituitary adenoma predisposition. Journal of Clinical
Endocrinology and Metabolism 2008 93 4146–4151.
18 Meyer BK, Petrulis JR & Perdew GH. Aryl hydrocarbon (Ah)
receptor levels are selectively modulated by hsp90-associated
immunophilin homolog XAP2. Cell Stress & Chaperones 2000 5
243–254.
19 Buchbinder S, Bierhaus A, Zorn M, Nawroth PP, Humpert P &
Schilling T. Aryl hydrocarbon receptor interacting protein gene
(AIP) mutations are rare in patients with hormone secreting or
non-secreting pituitary adenomas. Experimental and Clinical
Endocrinology & Diabetes 2008 116 625–628.
20 Bell DR & Poland A. Binding of aryl hydrocarbon receptor (AhR) to
AhR-interacting protein. The role of hsp90. Journal of Biological
Chemistry 2000 275 36407–36414.
21 Safe S. Molecular biology of the Ah receptor and its role in
carcinogenesis. Toxicology Letters 2001 120 1–7.
22 Carlson DB & Perdew GH. A dynamic role for the Ah receptor in
cell signaling? Insights from a diverse group of Ah receptor
interacting proteins Journal of Biochemical and Molecular Toxicology
2002 16 317–325.
23 de Oliveira SK, Hoffmeister M, Gambaryan S, Muller-Esterl W,
Guimaraes JA & Smolenski AP. Phosphodiesterase 2A forms a
complex with the co-chaperone XAP2 and regulates nuclear
translocation of the aryl hydrocarbon receptor. Journal of Biological
Chemistry 2007 282 13656–13663.
24 Vargiolu M, Fusco D, Kurelac I, Dirnberger D, Baumeister R,
Morra I, Melcarne A, Rimondini R, Romeo G & Bonora E. The
tyrosine kinase receptor RET interacts in vivo with AIP to
alter survivin availability. Journal of Clinical Endocrinology and
Metabolism 2009 94 2571–2578.
25 Yu R, Bonert V, Saporta I, Raffel LJ & Melmed S. Aryl hydrocarbon
receptor interacting protein variants in sporadic pituitary
adenomas. Journal of Clinical Endocrinology and Metabolism 2006
91 5126–5129.
26 DiGiovanni R, Serra S, Ezzat S & Asa SL. AIP mutations are not
identified in patients with sporadic pituitary adenomas. Endocrine
Pathology 2007 18 76–78.
27 Georgitsi M, De Menis E, Cannavo S, Makinen MJ, Tuppurainen K,
Pauletto P, Curto L, Weil RJ, Paschke R, Zielinski G, Wasik A,
Lubinski J, Vahteristo P, Karhu A & Aaltonen LA.www.eje-online.org
804 J E Jennings and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009) 161Aryl hydrocarbon receptor interacting protein (AIP) gene
mutation analysis in children and adolescents with sporadic
pituitary adenomas. Clinical Endocrinology 2008 69 621–627.
28 Georgitsi M, Karhu A, Winqvist R, Visakorpi T, Waltering K,
Vahteristo P, Launonen V & Aaltonen LA. Mutation analysis of
aryl hydrocarbon receptor interacting protein (AIP) gene in
colorectal, breast, and prostate cancers. British Journal of Cancer
2007 96 352–356.www.eje-online.org29 Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing
mortality in acromegaly. Journal of Clinical Endocrinology and
Metabolism 2004 89 667–674.Received 13 July 2009
Accepted 13 August 2009
